List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11396864/publications.pdf

Version: 2024-02-01

210 papers	28,830 citations	8159 76 h-index	5227 165 g-index
214 all docs	214 docs citations	214 times ranked	32542 citing authors

#	Article	IF	Citations
1	Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study. Science, 1998, 279, 563-566.	6.0	1,872
2	Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer, 2008, 8, 915-928.	12.8	1,792
3	Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet, The, 1998, 351, 1393-1396.	6.3	1,706
4	Diabetes and Cancer. Diabetes Care, 2010, 33, 1674-1685.	4.3	1,618
5	Metformin improves healthspan and lifespan in mice. Nature Communications, 2013, 4, 2192.	5.8	1,118
6	Metformin: From Mechanisms of Action to Therapies. Cell Metabolism, 2014, 20, 953-966.	7.2	1,019
7	Metformin Is an AMP Kinaseâ€“Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Research, 2006, 66, 10269-10273.	0.4	972
8	The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Reviews Cancer, 2012, 12, 159-169.	12.8	929
9	Metformin Inhibits Mammalian Target of Rapamycinâ€“Dependent Translation Initiation in Breast Cancer Cells. Cancer Research, 2007, 67, 10804-10812.	0.4	845
10	Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). Journal of the National Cancer Institute, 2001, 93, 1852-1857.	3.0	815
11	Diabetes and Cancer: A Consensus Report. Ca-A Cancer Journal for Clinicians, 2010, 60, 207-221.	157.7	724
12	mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation. Cell Metabolism, 2013, 18, 698-711.	7.2	647
13	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14134-14139.	3.3	447
14	mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle, 2015, 14, 473-480.	1.3	397
15	The Type 1 Insulin-Like Growth Factor Receptor Pathway. Clinical Cancer Research, 2008, 14, 6364-6370.	3.2	387
16	Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology, The, 2008, 9, 1039-1047.	5.1	385
17	Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer. Journal of the National Cancer Institute, 2002, 94, 1099-1106.	3.0	377
18	Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival. Cancer Research, 2008, 68, 10238-10246.	0.4	364

#	Article	IF	Citations
19	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	13.5	348
20	Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer & Metabolism, 2014, 2, 12.	2.4	330
21	A Prospective Study of Plasma C-Peptide and Colorectal Cancer Risk in Men. Journal of the National Cancer Institute, 2004, 96, 546-553.	3.0	311
22	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Annals of Internal Medicine, 2008, 149, 461.	2.0	263
23	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene, 2005, 24, 4281-4292.	2.6	251
24	mTOR as a central regulator of lifespan and aging. F1000Research, 2019, 8, 998.	0.8	244
25	Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. American Journal of Clinical Nutrition, 2009, 89, 634-640.	2.2	214
26	Metformin and Other Biguanides in Oncology: Advancing the Research Agenda. Cancer Prevention Research, 2010, 3, 1060-1065.	0.7	205
27	Insulin receptor expression by human prostate cancers. Prostate, 2009, 69, 33-40.	1.2	203
28	Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocrine-Related Cancer, 2010, 17, 351-360.	1.6	203
29	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer, 2004, 108, 334-341.	2.3	193
30	Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells. Journal of Biological Chemistry, 1996, 271, 1016-1021.	1.6	190
31	Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1274-1280.	1.8	178
32	nanoCAGE reveals 5â€² UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Research, 2016, 26, 636-648.	2.4	177
33	Distinct perturbation of the translatome by the antidiabetic drug metformin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8977-8982.	3.3	169
34	Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocrine-Related Cancer, 2008, 15, 833-839.	1.6	165
35	Potential applications for biguanides in oncology. Journal of Clinical Investigation, 2013, 123, 3693-3700.	3.9	162
36	Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts. Journal of the National Cancer Institute, 2007, 99, 1793-1800.	3.0	160

#	Article	IF	Citations
37	Mammary-specific deletion of parathyroid hormoneâ€“related protein preserves bone mass during lactation. Journal of Clinical Investigation, 2003, 112, 1429-1436.	3.9	156
38	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clinical Cancer Research, 2016, 22, 2283-2289.	3.2	154
39	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. Journal of Experimental Medicine, 2011, 208, 1809-1822.	4.2	153
40	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Antiâ€“Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 3196-3203.	0.8	152
41	Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast Cancer Cells. Biochemical and Biophysical Research Communications, 1997, 237, 690-693.	1.0	145
42	Insulin-like growth factors and prostate cancer. Cancer and Metastasis Reviews, 1998, 17, 383-390.	2.7	142
43	A study of highâ€dose oral silybinâ€phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate, 2010, 70, 848-855.	1.2	141
44	Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?. Cell Metabolism, 2016, 23, 569-570.	7.2	140
45	Insulin-Like Growth Factor-I, IGF-Binding Protein-3, and Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1065-1073.	1.1	134
46	Circulating IGF-I: New Perspectives for a New Century. Trends in Endocrinology and Metabolism, 1999, 10, 136-141.	3.1	128
47	IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors. Science Signaling, 2012, 5, ra92.	1.6	123
48	Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 337-344.	1.1	120
49	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Research and Treatment, 2012, 132, 131-142.	1.1	117
50	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research, 2016, 76, 2288-2300.	0.4	117
51	Insulin-Like Growth Factor Axis and Risk of Type 2 Diabetes in Women. Diabetes, 2012, 61, 2248-2254.	0.3	116
52	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. Cancer Prevention Research, 2017, 10, 235-243.	0.7	114
53	Serine Deprivation Enhances Antineoplastic Activity of Biguanides. Cancer Research, 2014, 74, 7521-7533.	0.4	113
54	Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell, 2018, 17, e12723.	3.0	113

#	Article	IF	Citations
55	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research, 2005, 7, R570-9.	2.2	112
56	Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 84-9.	1.1	112
57	Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. Endocrinology, 1998, 139, 807-810.	1.4	110
58	Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Research, 2016, 18, 1.	2.2	110
59	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research, 2008, 10, R86.	2.2	107
60	IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE, 2008, 3, e2578.	1.1	106
61	Genetic Factors Related to Racial Variation in Plasma Levels of Insulin-Like Growth Factor-1: Implications for Premenopausal Breast Cancer Risk. Molecular Genetics and Metabolism, 2001, 72, 144-154.	0.5	101
62	Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). European Urology, 2014, 66, 468-474.	0.9	100
63	The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model. Cancer Prevention Research, 2009, 2, 557-565.	0.7	98
64	Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells. Cancer Research, 2011, 71, 5754-5764.	0.4	97
65	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecologic Oncology, 2014, 134, 607-614.	0.6	97
66	Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma. Cancer Research, 2009, 69, 2443-2452.	0.4	96
67	Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. Nature Medicine, 2014, 20, 591-593.	15.2	95
68	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. , 1998, 69, 21-27.		94
69	Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Research, 2003, 63, 3991-4.	0.4	94
70	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism, 2018, 28, 679-688.e4.	7.2	92
71	Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1653-1659.	1.1	91
72	Targeting insulin and insulin-like growth factor signalling in oncology. Current Opinion in Pharmacology, 2008, 8, 384-392.	1.7	90

#	Article	IF	Citations
73	The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology. Clinical Cancer Research, 2012, 18, 40-50.	3.2	89
74	Insulin, insulin-like growth factors and neoplasia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 625-638.	2.2	85
75	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Research, 2005, 7, R796-807.	2.2	83
76	Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. International Journal of Cancer, 2004, 108, 773-779.	2.3	81
77	Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochemical and Biophysical Research Communications, 2011, 414, 694-699.	1.0	80
78	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. Journal of the National Cancer Institute, 2013, 105, 1881-1890.	3.0	80
79	The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia, 2017, 60, 1662-1667.	2.9	79
80	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1692-1701.	1.8	77
81	Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor. Molecular Pharmacology, 2006, 70, 1534-1541.	1.0	74
82	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. Clinical Cancer Research, 2008, 14, 6944-6954.	3.2	71
83	Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Medical Science Monitor, 2002, 8, BR521-6.	0.5	71
84	Prediagnostic Adiponectin Concentrations and Pancreatic Cancer Risk in Male Smokers. American Journal of Epidemiology, 2008, 168, 1047-1055.	1.6	70
85	Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Hormone and IGF Research, 2008, 18, 166-173.	0.5	65
86	eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nature Communications, 2019, 10, 5151.	5.8	64
87	ETV6-NTRK3â€“Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway. Cancer Research, 2011, 71, 1060-1070.	0.4	61
88	Translational and HIF-1Î±-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metabolism, 2018, 28, 817-832.e8.	7.2	61
89	A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene, 2005, 24, 4736-4740.	2.6	58
90	Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 880-888.	1.1	58

#	Article	IF	Citations
91	Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. Journal of Clinical Oncology, 2011, 29, 3605-3610.	0.8	57
92	Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density. Cancer Research, 2006, 66, 588-597.	0.4	55
93	Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology. Current Drug Targets, 2009, 10, 923-936.	1.0	55
94	Insulinâ€like growth factorâ€I, insulinâ€like growth factor binding proteinâ€3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate, 2008, 68, 1477-1486.	1.2	54
95	Insulin-Like Growth Factor-Related Signaling and Cancer Development. , 2007, 174, 49-53.		54
96	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. Clinical Cancer Research, 2008, 14, 8263-8269.	3.2	52
97	PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochemical and Biophysical Research Communications, 2005, 336, 1056-1061.	1.0	51
98	Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. International Journal of Cancer, 2012, 131, E105-13.	2.3	51
99	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2618-2627.	1.1	50
100	Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. American Journal of Epidemiology, 2015, 182, 187-197.	1.6	50
101	Synchronized Seasonal Variations of Mammographic Breast Density and Plasma 25-Hydroxyvitamin D. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 929-933.	1.1	49
102	Hypoxia-inducible factor-1Î± (HIF-1Î±) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate, 2007, 67, 1354-1361.	1.2	49
103	IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer, 2013, 20, 173-186.	1.6	48
104	A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 3407-3413.	3.2	47
105	Targeting Oxidative Phosphorylation: Why, When, and How. Cancer Cell, 2013, 23, 263-264.	7.7	47
106	IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors, 2010, 28, 243-255.	0.5	46
107	A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. Cancer Causes and Control, 2011, 22, 1627-1637.	0.8	46
108	Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy. BioDrugs, 2009, 23, 77-91.	2.2	45

#	Article	IF	Citations
109	Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortiumâ€. Human Molecular Genetics, 2010, 19, 3873-3884.	1.4	45
110	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. Journal of the National Cancer Institute, 2019, 111, 970-982.	3.0	43
111	Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis, 2013, 34, 109-112.	1.3	42
112	Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood, 2012, 120, 4929-4937.	0.6	41
113	Metformin, aging and cancer. Aging, 2013, 5, 330-331.	1.4	41
114	Protective effect of metformin in CD1 mice placed on a high carbohydrateâ€“high fat diet. Biochemical and Biophysical Research Communications, 2010, 397, 537-542.	1.0	40
115	Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. Journal of Clinical Oncology, 2017, 35, 3647-3653.	0.8	40
116	Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology, 1999, 54, 1120-1125.	0.5	39
117	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Hormone and IGF Research, 2000, 10, S32-S33.	0.5	39
118	Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. Journal of Clinical Investigation, 2016, 127, 132-136.	3.9	39
119	IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. PLoS ONE, 2016, 11, e0161158.	1.1	39
120	Metformin abolishes increased tumor18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. Cell Cycle, 2011, 10, 2770-2778.	1.3	38
121	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Research and Treatment, 2010, 122, 647-659.	1.1	37
122	A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. Cancer Causes and Control, 2012, 23, 959-965.	0.8	35
123	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Oncotarget, 2016, 7, 65643-65659.	0.8	35
124	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	1.3	35
125	Do Cancer Cells Care If Their Host Is Hungry?. Cell Metabolism, 2009, 9, 401-403.	7.2	34
126	Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2010, 3, 279-289.	0.7	33

#	Article	IF	Citations
127	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. Journal of the National Cancer Institute, 2014, 106, dju085.	3.0	33
128	Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Research, 2002, 62, 7372-6.	0.4	33
129	Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. International Journal of Cancer, 2006, 118, 1279-1284.	2.3	32
130	IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocrine-Related Cancer, 2011, 18, 699-709.	1.6	31
131	Metformin and Pancreatic Cancer: A Clue Requiring Investigation. Clinical Cancer Research, 2012, 18, 2723-2725.	3.2	31
132	Overexpression of ErbB2 receptor inhibits IGF-I-induced Shcâ€“MAPK signaling pathway in breast cancer cells. Biochemical and Biophysical Research Communications, 2004, 313, 709-715.	1.0	30
133	Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochemical and Biophysical Research Communications, 2004, 316, 421-428.	1.0	30
134	Reduced growth of human sarcoma xenografts in hosts homozygous for thelit mutation. Journal of Surgical Oncology, 2002, 81, 75-79.	0.8	29
135	The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Letters, 2007, 255, 300-306.	3.2	29
136	Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts. PLoS ONE, 2013, 8, e79710.	1.1	29
137	Serum Insulin-Like Growth Factor-I Levels and Prostatic Intraepithelial Neoplasia: A Clue to the Relationship Between IGF-I Physiology and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1270-1273.	1.1	28
138	Insulin-Like Growth Factors and Insulin-Like Growth Factorâ€“Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2013, 6, 91-99.	0.7	28
139	Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Letters, 2010, 289, 246-253.	3.2	27
140	Metastatic Breast Carcinomaâ€“Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. Clinical Cancer Research, 2019, 25, 7229-7242.	3.2	26
141	The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Advances in Urology, 2012, 2012, 1-11.	0.6	24
142	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nature Communications, 2021, 12, 3299.	5.8	24
143	HH2A, an immortalized bovine mammary epithelial cell line, expresses the gene encoding mammary derived growth inhibitor (MDGI). In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 25-29.	0.7	23
144	Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. Prostate, 2010, 70, 1628-1635.	1.2	23

#	Article	IF	Citations
145	Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clinical Genitourinary Cancer, 2019, 17, e323-e328.	0.9	23
146	Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate Biopsy. Journal of Urology, 2002, 168, 2426-2430.	0.2	22
147	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1281-1288.	1.1	22
148	Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 438-44.	1.1	22
149	Insulin-like growth factor physiology and neoplasia. Growth Hormone and IGF Research, 2000, 10, S6-S7.	0.5	21
150	Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. American Journal of Clinical Nutrition, 2006, 84, 1518-1526.	2.2	21
151	Plasma Insulinlike Growth Factor 1 and Binding-Protein 3 and Risk of Myocardial Infarction in Women: A Prospective Study. Clinical Chemistry, 2008, 54, 1682-1688.	1.5	21
152	Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget, 2017, 8, 50542-50556.	0.8	21
153	Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Molecular Metabolism, 2022, 61, 101498.	3.0	21
154	IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Experimental Hematology, 2012, 40, 715-723.e6.	0.2	20
155	The role of GSK3 in metabolic pathway perturbations in cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119059.	1.9	20
156	Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgenâ€independent progression. Prostate, 2011, 71, 525-537.	1.2	19
157	Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. Molecular and Cellular Biochemistry, 1999, 199, 41-48.	1.4	18
158	Risk of cancer after growth-hormone treatment. Lancet, The, 2002, 360, 268-269.	6.3	18
159	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1402-1410.	1.1	18
160	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes and Control, 2012, 23, 779-784.	0.8	18
161	Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study. Diabetes Care, 2014, 37, 134-143.	4.3	18
162	Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes In Vitro and in Male C57BL/6 Mice. Endocrinology, 2014, 155, 703-715.	1.4	18

#	Article	IF	Citations
163	Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Research, 2016, 18, 24.	2.2	18
164	Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia, 2021, 23, 391-399.	2.3	18
165	Levels of C-Peptide and Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2661-2664.	1.1	17
166	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. Journal of the National Cancer Institute, 2014, 106, .	3.0	16
167	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Molecular and Cellular Endocrinology, 2014, 384, 117-125.	1.6	16
168	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with â^¼240-Fold Higher Drug Concentration in Urine than Serum. Molecular Cancer Therapeutics, 2016, 15, 430-438.	1.9	16
169	Metabolic heterogeneity signature of primary treatment-naÃ¯ve prostate cancer. Oncotarget, 2017, 8, 25928-25941.	0.8	16
170	Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. Breast Cancer Research and Treatment, 2015, 149, 577-585.	1.1	15
171	Other novel agents: Rationale and current status as chemopreventive agents. Urology, 2001, 57, 86-89.	0.5	14
172	Effect of Isocaloric Low Fat Diet on Prostate Cancer Xenograft Progression in a Hormone Deprivation Model. Journal of Urology, 2010, 183, 1619-1624.	0.2	14
173	Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 267-278.	1.8	14
174	Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients, 2017, 9, 378.	1.7	14
175	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGFâ€I, IGFâ€II, IGFBPâ€1, IGFBPâ€2 and IGFBPâ€3 in a pooled analysis of 16,024 men from 22 studies. International Journal of Cancer, 2019, 145, 3244-3256.	2.3	14
176	Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. Cancer Prevention Research, 2021, 14, 541-550.	0.7	13
177	Tissue-Specific Targeting of the Pthrp Gene: The Generation of Mice with Floxed Alleles. , 0, .		13
178	Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: Correlations with effects on proliferation: A review. Progress in Growth Factor Research, 1995, 6, 495-501.	1.7	12
179	Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. Breast Cancer Research, 2008, 10, R42.	2.2	12
180	Serum transforming growth factor-Î²1 and risk of pancreatic cancer in three prospective cohort studies. Cancer Causes and Control, 2014, 25, 1083-1091.	0.8	12

#	Article	IF	Citations
181	Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 914-922.	1.1	11
182	Insulin-like growth factor 1 receptor stabilizes the ETV6â€“NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation. Journal of Biological Chemistry, 2018, 293, 12502-12515.	1.6	11
183	Binding between Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 3 Is Not Influenced by Glucose or 2-Deoxy-d-glucose. Journal of Biological Chemistry, 2011, 286, 16567-16573.	1.6	10
184	Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocrine-Related Cancer, 2012, 19, 557-574.	1.6	10
185	Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. PLoS ONE, 2016, 11, e0167832.	1.1	10
186	The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4541-4547.	1.8	10
187	Interplay between ShcA Signaling and PGC-1Î± Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. Cancer Research, 2018, 78, 4826-4838.	0.4	10
188	Relationship of circulating insulin-like growth factor-I and binding proteins 1â€“7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. Breast Cancer Research, 2019, 21, 81.	2.2	10
189	Metformin and Hepatic Carcinogenesis. Cancer Prevention Research, 2012, 5, 500-502.	0.7	9
190	Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. Journal of Molecular Endocrinology, 2019, 62, R83-R103.	1.1	9
191	Exercise Does Not Counteract the Effects of a â€œWesternizedâ€•Diet on Prostate Cancer Xenografts. Prostate, 2013, 73, 1223-1232.	1.2	8
192	Serum insulinâ€like growth factor (IGF)â€ and IGF binding proteinâ€ in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. International Journal of Cancer, 2018, 143, 496-507.	2.3	8
193	Energy Metabolism, Cancer Risk, and Cancer Prevention. Recent Results in Cancer Research, 2009, 181, 51-54.	1.8	8
194	Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. Annals of Surgical Oncology, 2017, 24, 3212-3219.	0.7	7
195	Macronutrient Intake and Cancer: How Does Dietary Restriction Influence Tumor Growth and Why Should We Care?. Cancer Prevention Research, 2009, 2, 698-701.	0.7	6
196	Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. Growth Hormone and IGF Research, 2016, 26, 11-16.	0.5	6
197	A phenotype of IGFBPâ€ knockout mice revealed by dextran sulfateâ€induced colitis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 146-153.	1.4	6
198	Circulating Insulin-Like Growth Factor 1â€“Related Biomarkers and Risk of Lethal Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, pkab091.	1.4	6

#	Article	IF	Citations
199	Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. Npj Breast Cancer, 2021, 7, 18.	2.3	5
200	Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome. Carcinogenesis, 2021, 42, 1281-1292.	1.3	5
201	Insulin-like growth factor-I and risk of breast cancer. Lancet, The, 1998, 352, 489.	6.3	3
202	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. Genes and Cancer, 2013, 4, 535-545.	0.6	3
203	Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. Growth Hormone and IGF Research, 2014, 24, 142-149.	0.5	3
204	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. Journal of Cancer Epidemiology, 2015, 2015, 1-7.	0.5	3
205	Aging, IGFâ€1, and diet. Aging Cell, 2009, 8, 214-214.	3.0	1
206	Beyond steroid hormones: the new cancer endocrinology. Lancet Oncology, The, 2010, 11, 501-502.	5.1	1
207	Translational and HIF11-Dependent Metabolic Reprograming Underpin Oncometabolome Plasticity and Synergy Between Oncogenic Kinase Inhibitors and Biguanides. SSRN Electronic Journal, 0, , .	0.4	1
208	Individualizing Interventions for Cancer Prevention. , 2005, 166, 63-70.		0
209	The insulinâ€“insulin-like growth-factor receptor family as a therapeutic target in oncology. , 0, , 110-118.		0
210	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. Journal of Cell Biology, 2011, 194, i8-i8.	2.3	0